sinapultide profile

sinapultide: RN & amino acid sequence in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

Synonym
sinapultide [usan:inn]
rwj 45652
unii-040x3ax99t
sinapultide
ati 01
l-lysyl-l-leucyl-l-leucyl-l-leucyl-l-leucyl-l-lysyl-l-leucyl-l-leucyl-l-leucyl-l-leucyl-l-lysyl-l-leucyl-l-leucyl-l-leucyl-l-leucyl-l-lysyl-l-leucyl-l-leucyl-l-leucyl-l-leucyl-l-lysine
040x3ax99t ,
l-lysine, l-lysyl-l-leucyl-l-leucyl-l-leucyl-l-leucyl-l-lysyl-l-leucyl-l-leucyl-l-leucyl-l-leucyl-l-lysyl-l-leucyl-l-leucyl-l-leucyl-l-leucyl-l-lysyl-l-leucyl-l-leucyl-l-leucyl-l-leucyl-
kl4 (peptide)
138531-07-4
peptide kl-4
peptide kl4
rwj-45652
kl4 peptide
ati-01
CHEMBL2103901
SCHEMBL180504
DTXSID30160707
DB11332

Sinapultide-loaded MBs combined with ultrasonic treatment may be a new therapeutic option for lung injury diseases in the clinic.

Excerpt	Reference
" In this study, sinapultide-loaded microbubbles (MBs) were prepared and combined with ultrasound (US) treatment as a new strategy for improved treatment of lung injury diseases."	( Sinapultide-Loaded Microbubbles Combined with Ultrasound to Attenuate Lipopolysaccharide-Induced Acute Lung Injury in Mice. Chen, C; Chen, Y; Han, B; Li, F; Liu, D; Wei, P; Xiao, D, 2020)
"The combination treatment strategy of MBs combined with ultrasound was tested in a lipopolysaccharide (LPS)-induced mouse model of alveolar epithelial cells (AT II) and acute lung injury."	( Sinapultide-Loaded Microbubbles Combined with Ultrasound to Attenuate Lipopolysaccharide-Induced Acute Lung Injury in Mice. Chen, C; Chen, Y; Han, B; Li, F; Liu, D; Wei, P; Xiao, D, 2020)
"Sinapultide-loaded MBs in combination with ultrasound treatment significantly reduced the secretion of inflammatory cytokines and increased the expression of surfactant protein A (SP-A) in AT II cells."	( Sinapultide-Loaded Microbubbles Combined with Ultrasound to Attenuate Lipopolysaccharide-Induced Acute Lung Injury in Mice. Chen, C; Chen, Y; Han, B; Li, F; Liu, D; Wei, P; Xiao, D, 2020)
"Sinapultide-loaded MBs combined with ultrasonic treatment may be a new therapeutic option for lung injury diseases in the clinic."	( Sinapultide-Loaded Microbubbles Combined with Ultrasound to Attenuate Lipopolysaccharide-Induced Acute Lung Injury in Mice. Chen, C; Chen, Y; Han, B; Li, F; Liu, D; Wei, P; Xiao, D, 2020)

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (20.00)	18.2507
2000's	3 (60.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (20.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (20.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	4 (80.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
phosphorylcholine Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.. phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.	3.14	1	phosphocholines	allergen; epitope; hapten; human metabolite; mouse metabolite
1,2-dipalmitoylphosphatidylcholine 1,2-Dipalmitoylphosphatidylcholine: Synthetic phospholipid used in liposomes and lipid bilayers to study biological membranes. It is also a major constituent of PULMONARY SURFACTANTS.	2.02	1
dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination: protein-free, synthetic surfactant containing dipalmitoylphosphatidylcholine, hexadecanol & tyloxapol; used in treatment of respiratory distress syndrome	3.14	1
brefeldin a [no description available]	2.02	1	macrolide antibiotic	Penicillium metabolite
lucinactant lucinactant: a pulmonary surfactant composed of sinapultide, colfosceril palmitate, palmitoyloleaoylphosphatidylglycerol, and palmitic acid	3.14	1

Condition	Relationship Strength	Studies
Lung Injury, Acute [description not available]	2.25	1
Acute Lung Injury A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).	7.25	1
Infantile Respiratory Distress Syndrome [description not available]	3.34	2
Respiratory Distress Syndrome, Newborn A condition of the newborn marked by DYSPNEA with CYANOSIS, heralded by such prodromal signs as dilatation of the alae nasi, expiratory grunt, and retraction of the suprasternal notch or costal margins, mostly frequently occurring in premature infants, children of diabetic mothers, and infants delivered by cesarean section, and sometimes with no apparent predisposing cause.	3.34	2
Adenocarcinoma, Basal Cell [description not available]	2.02	1
Cancer of Lung [description not available]	2.02	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.02	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.02	1
Acute Respiratory Distress Syndrome [description not available]	1.99	1
Respiratory Distress Syndrome A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.	1.99	1